What is STTK's current stock price?

STTK (Shattuck Labs, Inc.) is currently trading at $6.10 with a market cap of $292.2M.

What sector is Shattuck Labs, Inc. in?

Shattuck Labs, Inc. (STTK) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is STTK a good stock to buy?

Analysts have a Buy consensus on STTK with a price target of $14.67. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

STTK Shattuck Labs, Inc.

Healthcare

$6.10+0.16%ClosedMarket Cap: $292.2M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

7.14

P/S

292.21

EV/EBITDA

-4.27

DCF Value

$0.62

FCF Yield

-14.1%

Div Yield

0.0%

Margins & Returns

Gross Margin

-82.0%

Operating Margin

-5266.4%

Net Margin

-4987.4%

ROE

-60.7%

ROA

-48.8%

ROIC

-53.8%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-14.8M	$—
Q4 null	$0.00	$-12.6M	$—
FY null	$1.0M	$-48.8M	$—
Q3 null	$1.0M	$-10.1M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$14.67

Target (Median)

$15.00

Target Range

$11.00 - $18.00

2 Strong Buy5 Buy1 Hold0 Sell0 Strong Sell

WedbushOutperform

2026-05-08

HC Wainwright & Co.Buy

2026-04-20

CitigroupNeutral

2026-03-13

WedbushOutperform

2026-03-06

CitigroupNeutral

2026-01-06

Trading Activity

Insider Trades

View All

Shukla Abhinav A.officer: Chief Technical Officer

SellThu May 21

Shukla Abhinav A.officer: Chief Technical Officer

SellThu May 21

Stout Stephenofficer: See Remarks

SellMon May 18

Stout Stephenofficer: See Remarks

SellMon May 18

Shukla Abhinav A.officer: Chief Technical Officer

SellThu May 14

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

1.19

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.

Peers

IMA

MGX